Kintara Therapeutics Files 8-K

TL;DR

KINTARA THERAPEUTICS (KTRA) FILED AN 8-K ON 9/11/24 COVERING FINANCIALS AND OTHER EVENTS.

AI Summary

Kintara Therapeutics, Inc. filed an 8-K on September 11, 2024, reporting on various events. The filing includes information related to financial statements and exhibits, as well as other events and a Regulation FD disclosure. The company, formerly known as DelMar Pharmaceuticals, Inc., is incorporated in Nevada and headquartered in San Diego, California.

Why It Matters

This 8-K filing provides updates on Kintara Therapeutics' corporate activities, including financial reporting and other material events, which are important for investors to monitor the company's status.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.

Key Players & Entities

• Kintara Therapeutics, Inc. (company) — Registrant
• DelMar Pharmaceuticals, Inc. (company) — Former company name
• September 11, 2024 (date) — Date of report
• Nevada (jurisdiction) — State of incorporation
• San Diego, California (location) — Principal executive offices

FAQ

Key Financial Figures

• $2.0 million — the REM-001 study is being covered by a $2.0 million Small Business Innovation Research (SBI

Filing Documents

• ktra-20240911.htm (8-K) — 71KB
• ktra-ex99_1.htm (EX-99.1) — 41KB
• ktra-ex99_2.htm (EX-99.2) — 23KB
• img40499469_0.jpg (GRAPHIC) — 113KB
• img41422990_0.jpg (GRAPHIC) — 24KB
• 0000950170-24-105344.txt ( ) — 465KB
• ktra-20240911.xsd (EX-101.SCH) — 27KB
• ktra-20240911_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 11, 2024, Kintara Therapeutics, Inc. (" Kintara ") issued a press release providing corporate and REM-001 clinical study updates. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. In addition, on or about September 11, 2024, Kintara distributed a letter to certain stockholders regarding the Special Meeting of Stockholders (the " Special Meeting ") to allow for completion of the proposed merger (the " Merger ") with TuHURA Biosciences, Inc. (" TuHURA "). A copy of the letter is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference herein. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1 and Exhibit 99.2, is being furnished to the Securities and Exchange Commission (the " SEC "), and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

01. Other Events

Item 8.01. Other Events. On September 11, 2024, Kintara provided a corporate and REM-001 clinical study update. Corporate Updates In April 2024, Kintara and TuHURA entered into definitive merger agreement (the " Merger Agreement "), pursuant to which Kayak Mergeco, Inc., Kintara's wholly-owned subsidiary, will merge with and into TuHURA, with TuHURA surviving the proposed Merger and becoming Kintara's direct, wholly-owned subsidiary. o Kintara's existing stockholders will own approximately 5.45% of combined company's common stock at the closing of the proposed Merger on a pro forma fully diluted basis, inclusive of the contingent value rights (" CVRs ") to receive shares of common stock of the combined company upon the achievement of enrollment of a minimum of 10 patients in the REM-001 study, with such patients each completing 8 weeks of follow-up on or before December 31, 2025 (the " Milestone "). Special Meeting of Stockholders (the " Special Meeting ") to obtain stockholder approval of the proposals set forth in Kintara's proxy statement for the Special Meeting required to allow for completion of the proposed Merger with TuHURA will be held virtually on Friday, September 20, 2024, at 9:00 a.m., Eastern Time via live audio webcast. In order to attend, register in advance at www.viewproxy.com/kintarasm/2024 by 11:59 p.m., Eastern Time, on September 19, 2024. Kintara stockholders of record on August 14, 2024 (the " Record Date ") are eligible to vote even if not a stockholder after the Record Date. o Stockholders immediately prior to the closing of the proposed Merger, even if not a stockholder on the Record Date, are eligible to receive CVRs, entitling such holders to receive shares of common stock of the combined company upon achievement of the Milestone. REM-001 Clinical Study Update As of September 10, 2024 the REM-001 study in patients with cutaneous metastatic breast cancer (" CMBC ") has enrolled four of the 10 patients needed to reach the mi

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K and the communication attached hereto as Exhibit 99.1 and Exhibit 99.2 contain forward-looking statements based upon Kintara's and TuHURA's current expectations. This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by terminology such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely" or the negative or plural of these words or similar expressions. These statements are only predictions. Kintara and TuHURA have based these forward-looking statements largely on their then-current expectations and projections about future events, as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond each of Kintara's and TuHURA's control, and actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: (i) the risk that the conditions to the closing or consummation of the proposed Merger are not satisfied, including the failure to obtain Kintara stockholder approval for the proposed Merger; (ii) uncertainties as to the timing of the consummation of the proposed Merger and the ability of each of Kintara and TuHURA to consummate the transactions contemplated by the proposed Merger; (iii) risks related to Kintara's and TuHURA's ability to correctly estimate their respective operating expenses and expenses associated with the proposed Merger, as applicable, as well as uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of the resulting combined company upon closing and other events and unanticipated spending

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release of Kintara Therapeutics, Inc. issued September 11, 2024. 99.2 Letter to Kintara Therapeutics, Inc. Stockholders. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KINTARA THERAPEUTICS, INC. Date: September 11, 2024 By: /s/ Robert E. Hoffman Name: Robert E. Hoffman Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR